Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres

Treatment with monoclonal antibodies was associated with improved survival in COVID-19 after lung transplantation (LTx). Age was a negative independent predictor of survival in this cohort of 133 COVID-19 cases after LTx. https://bit.ly/3kx5CBw

Detalles Bibliográficos
Autores principales: Gottlieb, Jens, Kolditz, Martin, Gade, Nils, Welte, Tobias, Kneidinger, Nikolaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301052/
https://www.ncbi.nlm.nih.gov/pubmed/35618274
http://dx.doi.org/10.1183/13993003.00124-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301052/
https://www.ncbi.nlm.nih.gov/pubmed/35618274
http://dx.doi.org/10.1183/13993003.00124-2022

Ejemplares similares